Hermia Theranostics is a sophisticated, state-of-the-art, and vendor-neutral software suite developed by Hermes Medical Solutions for molecular imaging and dosimetry. It provides an all-in-one platform to facilitate fast, accurate, and personalized diagnosis and therapies in nuclear medicine, including planar Nuclear Medicine, PET, SPECT, CT, and MRI, irrespective of the camera manufacturer. The core focus is on Theranostics (simultaneous therapy and diagnostic), enabling individualized dosimetry for each patient to optimize outcomes and deliver cost-effective, cutting-edge treatments.
Key Features & Capabilities: Hermia offers a comprehensive toolkit for displaying and analyzing nuclear medicine images across multiple modalities. Core features include:
- Voxel Dosimetry: Utilizes a voxel-based Monte-Carlo algorithm to reduce the inaccuracy of planar-based models by 2 to 3 fold, providing personalized dosimetry for a wide range of therapy and imaging isotopes.
- SIRT (Selective Internal Radiation Therapy) Application: Delivers a streamlined workflow for dosimetry planning and verification, aligning with EANM guidelines. It features computer-assisted CT segmentation of the liver and lungs and live dose optimization feedback.
- Quantitative SPECT Reconstruction: Advanced algorithms compensate for attenuation, scatter, and resolution loss, enabling accurate quantitative results like SUV (Standardized Uptake Value) calculations.
- AI & Automation: Exploits AI and computing technology to accelerate reporting with features like computer-assisted organ segmentation, automated lesion tracking, and AI-driven motion correction.
- Theranostic Dashboard: Optimizes patient-specific activity injections while ensuring safe dose limits for all available radiopharmaceuticals.
Target Users and Use Cases: The primary target users are nuclear medicine physicians, dosimetrists, physicists, and technologists in hospitals and imaging centers. Use cases include personalized treatment planning and verification for oncological applications such as metastatic prostate cancer (PSMA PET scan), liver cancer (SIRT), and neuroendocrine tumors. The software aims to simplify complex workflows, standardize results, and provide robust decision support.